Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotech company focused on neuropsychiatric disorder treatments, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's President and CEO, Dr. Spyros Papapetropoulos, will deliver a presentation at the conference, which takes place September 8-10, 2025 in New York. The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET, accessible through both the conference platform and Neuphoria's investor relations website.
Neuphoria Therapeutics (Nasdaq: NEUP), società biofarmaceutica in fase clinica focalizzata sui trattamenti per i disturbi neuropsichiatrici, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference.
Il Presidente e CEO della società, Dr. Spyros Papapetropoulos, terrà una presentazione alla conferenza, che si svolgerà dal 8 al 10 settembre 2025 a New York. La presentazione sarà disponibile on-demand a partire dal 5 settembre 2025 alle 7:00 ET, accessibile sia tramite la piattaforma della conferenza che dal sito per gli investitori di Neuphoria.
Neuphoria Therapeutics (Nasdaq: NEUP), una compañía biotecnológica en etapa clínica centrada en tratamientos para trastornos neuropsiquiátricos, ha anunciado su participación en la H.C. Wainwright 27th Annual Global Investment Conference.
El Presidente y CEO de la empresa, Dr. Spyros Papapetropoulos, ofrecerá una presentación en la conferencia, que tendrá lugar del 8 al 10 de septiembre de 2025 en Nueva York. La presentación estará disponible on-demand a partir del 5 de septiembre de 2025 a las 7:00 a.m. ET, y podrá consultarse tanto en la plataforma de la conferencia como en la web de relaciones con inversores de Neuphoria.
Neuphoria Therapeutics (Nasdaq: NEUP)는 신경정신과 질환 치료제 개발에 주력하는 임상 단계의 바이오텍 기업으로, 다가오는 H.C. Wainwright 27th Annual Global Investment Conference에 참가한다고 발표했습니다.
회사의 사장 겸 CEO인 Dr. Spyros Papapetropoulos가 콘퍼런스에서 발표를 진행하며, 행사는 2025년 9월 8일~10일 뉴욕에서 열립니다. 발표 자료는 2025년 9월 5일 오전 7:00(동부시간)부터 온디맨드로 제공되며, 콘퍼런스 플랫폼과 Neuphoria의 투자자 관계 웹사이트에서 확인할 수 있습니다.
Neuphoria Therapeutics (Nasdaq: NEUP), une société biotechnologique en phase clinique spécialisée dans les traitements des troubles neuropsychiatriques, a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference.
Le président-directeur général de la société, Dr. Spyros Papapetropoulos, fera une présentation lors de la conférence, qui se tiendra du 8 au 10 septembre 2025 à New York. La présentation sera disponible à la demande à partir du 5 septembre 2025 à 7h00 ET, accessible via la plateforme de la conférence ainsi que le site relations investisseurs de Neuphoria.
Neuphoria Therapeutics (Nasdaq: NEUP), ein klinisch geführtes Biotech-Unternehmen, das sich auf Behandlungen neuropsychiatrischer Erkrankungen spezialisiert hat, gab seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference bekannt.
Der Präsident und CEO des Unternehmens, Dr. Spyros Papapetropoulos, wird auf der Konferenz eine Präsentation halten, die vom 8. bis 10. September 2025 in New York stattfindet. Die Präsentation wird ab dem 5. September 2025 um 7:00 Uhr ET on-demand verfügbar sein und kann sowohl über die Konferenzplattform als auch über die Investor-Relations-Website von Neuphoria abgerufen werden.
- None.
- None.
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that Spyros Papapetropoulos, M.D., Ph.D., President and CEO, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
The presentation will be available on demand here starting on Friday, September 5 at 7:00 a.m. ET. The webcast will also be available on the “Events” page in the investors section of Neuphoria’s website.
About Neuphoria Therapeutics Inc.
Neuphoria (Nasdaq: NEUP) is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC-210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, “as needed” treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC-210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Neuphoria's pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Spyridon (Spyros) Papapetropoulos info@neuphoriatx.com | IR & PR Argot Partners neuphoria@argotpartners.com |
FAQ
When is Neuphoria Therapeutics (NEUP) presenting at the H.C. Wainwright Conference?
Who will be presenting for Neuphoria Therapeutics at the H.C. Wainwright Conference?
How can investors access Neuphoria Therapeutics' (NEUP) H.C. Wainwright presentation?
What type of company is Neuphoria Therapeutics (NEUP)?
